All In Biotech

Drug Trial Radar · NCT06606730

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

OPTimizing Adjuvant Prescription of PEMBROlizumab in Patients With Early-stage Triple-negative Breast Cancer Achieving Pathologic Complete Response After Standard Neoadjuvant Chemotherapy and Pembrolizumab

Last checked: Nov 20, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,454 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,454

Planned (sponsor's estimate)

Start

Jul 23, 2025

Primary completion

Jan 1, 2033

Study completion Jun 1, 2039

Sponsor

Lead sponsor
UNICANCERAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

OPT-PEMBRO trial is a pragmatic, multicentre, international, prospective, non-inferiority, two-arms, randomised (1:1), open-label, Phase III clinical study. The main goal of this research is to determine if patients with triple-negative breast cancer, who experience a complete response after neoadjuvant treatment, have the same chance of avoiding cancer recurrence whether they stop pembrolizumab or continue taking it for an additional 6 months. This research will also take into account patients tolerance to treatment and quality of life.

Conditions

  • Breast Cancers
  • Triple Negative Breast Cancer (TNBC)

Interventions

  • PembrolizumabDrug

    Administration of pembrolizumab for 6 months

  • DeescalationOther

    Patients will be followed up according to standard practice for 4 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free survivalTime frame: From randomization to disease progression or death, up to 8 years.

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint Luc Brussels

    Brussels, Belgium · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.